Puma Biotech punts near $300 million on Takeda discard
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
PUMA Biotechnology, Inc. Form S-1
Puma Biotechnology Careers | Wellfound (formerly AngelList Talent)
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer | Business Wire
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | The Motley Fool
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Product Pipeline
Puma Biotechnology, Inc.
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
PUMA BIOTECHNOLOGY, INC.
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y
Puma Biotechnology
Knight Therapeutics licences cancer drug from Puma Biotechnology
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Why Puma Biotechnology's Shares Jumped 20% on Monday | The Motley Fool
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
